subject: One Step Closer for Female Sexual Dysfunction [print this page] One Step Closer for Female Sexual Dysfunction
There is on-going debate circulating over the veracity of the claim that sexual dysfunction in women is a treatable condition. Thanks to the one sided viewpoint of Mr. Ray Moynihan of Sex, Lies and Pharmaceuticals, people are jumping over to his side of the fence to hear him explain that female sexual dysfunction is a figment of the imagination, a mere ploy invented by the pharmaceutical companies in order to make some money out of tired working mothers who are being made to think that they have a medical condition.
A review in The Obstetrician and Gynaecologist (TOG) discusses the condition from the perspective of the medical community. Simultaneously, it describes the inadequate advice and attention given to this dysfunction by many of the community given the lack of awareness surrounding it. They explain that that the GP is the most important advisor in this circumstance as he or she will be the woman's first point of contact. The discussion of sexual dysfunction is considered an important part of the treatment process. Being able to discuss sexual problems freely and openly is half the battle.
Hypoactive Sexual Desire Disorder (HSDD) is one of the most common types of sexual dysfunction. It is defined by a continual absence of sexual thought or responsiveness to sexual activity resulting in distress. The review is based on the experiences of 2467 women between the ages of 20 and 70 years of age where the relationship between HSDD and aging was observed. It was discovered that HSDD occurred among women who had had their wombs removed. Furthermore, women who have had an oophorectomy experience a sudden decline in testosterone levels resulting in a significant decrease in androgens. Androgens directly affect sexual desire, arousal and orgasm suggesting that testosterone deficiency is a likely cause of HSSD.
A decline in estradiol levels amongst women who have had the menopause will affect sexual function. In this case the review recommends oestrogen replacement as the most suitable therapy.
Sexual dysfunction effects people differently and treatments will vary. As it is such a source of distress for women, the medical community really need to be ready to communicate freely on this matter and be prepared to become more knowledgeable regarding FSD.
Research and publications such as this review are vital for the development of awareness so that more advanced treatments can be trialled and approved and so that outrageous claims such as those preached in Sex, Lies and Pharmaceuticals may be negated.
Most recently the application to extend the treatment scope for Intrinsa was withdrawn and the reasons are still unknown. Awareness is paramount in this situation and communication is the key.
Intrinsa is available for purchase at The Online Clinic. Intrinsa is a testosterone replacement therapy that treats the problem of Hypoactive Sexual Desire Disorder in women.
welcome to Insurances.net (https://www.insurances.net)
